688 related articles for article (PubMed ID: 34378098)
21. Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination.
Ikediobi O; Eichenfield DZ; Barrio VR
Pediatr Dermatol; 2022 Sep; 39(5):823-824. PubMed ID: 35522122
[TBL] [Abstract][Full Text] [Related]
22. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
Fornaro M; Venerito V; Iannone F; Cacciapaglia F
J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
[No Abstract] [Full Text] [Related]
23. Response to: There is not enough evidence to support the claim that Covid-19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count.
Gat I; Kedem A; Dviri M; Hourvitz A; Baum M
Andrology; 2023 Jan; 11(1):8-9. PubMed ID: 36306197
[No Abstract] [Full Text] [Related]
24. Aseptic Meningitis Following the Second Dose of Comirnaty Vaccination in an Adolescent Patient: A Case Report.
Lee JK
Pediatr Infect Dis J; 2022 Feb; 41(2):172-174. PubMed ID: 34711784
[TBL] [Abstract][Full Text] [Related]
25. The association between COVID-19 vaccination and Bell's palsy.
Cirillo N; Doan R
Lancet Infect Dis; 2022 Jan; 22(1):5-6. PubMed ID: 34411533
[No Abstract] [Full Text] [Related]
26. Severe acute interstitial lung disease after BNT162b2 mRNA COVID-19 vaccination in a patient post HLA-haploidentical hematopoietic stem cell transplantation.
Ueno T; Ohta T; Sugio Y; Ohno Y; Uehara Y
Bone Marrow Transplant; 2022 May; 57(5):840-842. PubMed ID: 35273388
[No Abstract] [Full Text] [Related]
27. Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination.
Caocci G; Fanni D; Porru M; Greco M; Nemolato S; Firinu D; Faa G; Scuteri A; La Nasa G
Haematologica; 2022 May; 107(5):1222-1225. PubMed ID: 34965702
[No Abstract] [Full Text] [Related]
28. Cutaneous lupus-erythematosus-like reaction arising after COVID-19 vaccination.
Rose C; Apgar R; Green M
J Cutan Pathol; 2022 Nov; 49(11):943-946. PubMed ID: 35754159
[TBL] [Abstract][Full Text] [Related]
29. Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
Juddoo V; Juddoo S; Mégarbane B
Vaccine; 2022 Apr; 40(19):2650-2651. PubMed ID: 35365342
[No Abstract] [Full Text] [Related]
30. [Erythema multiforme following COVID-19 vaccination (BNT162b2)].
Wunderlich K; Dirschka T
Hautarzt; 2022 Jan; 73(1):68-70. PubMed ID: 34676438
[TBL] [Abstract][Full Text] [Related]
31. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
Scorza FA; Finsterer J
Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
[No Abstract] [Full Text] [Related]
32. BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study.
Lim XR; Leung BP; Sum CLL; Lim GH; Chua CG; Tu TM; Ramanathan K; Huang MY; Howe HS; Fan BE
Am J Hematol; 2022 Apr; 97(4):E141-E144. PubMed ID: 35015303
[No Abstract] [Full Text] [Related]
33. Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty.
Chien KJ; Chen CY; Lin CC; Cheng MF; Weng KP
Pediatr Neonatol; 2023 May; 64(3):359-361. PubMed ID: 36682910
[No Abstract] [Full Text] [Related]
34. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
[TBL] [Abstract][Full Text] [Related]
35. Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents.
Lam CY; Chang L; Lin SM
Pediatr Neonatol; 2023 Jul; 64(4):487-488. PubMed ID: 37012100
[No Abstract] [Full Text] [Related]
36. Two cases of axillary lymphadenopathy diagnosed as diffuse large B-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination.
Mizutani M; Mitsui H; Amano T; Ogawa Y; Deguchi N; Shimada S; Miwa A; Kawamura T; Ogido Y
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e613-e615. PubMed ID: 35398921
[No Abstract] [Full Text] [Related]
37. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre.
Koumaki D; Krueger-Krasagakis SE; Papadakis M; Katoulis AC; Gkiaouraki I; Zografaki K; Mylonakis D; Krasagakis K
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e411-e415. PubMed ID: 35075691
[No Abstract] [Full Text] [Related]
38. Liver injury and cytopenia after BNT162b2 COVID-19 vaccination in an adolescent.
Kawasaki Y; Matsubara K; Hori M; Isome K
Pediatr Int; 2022 Jan; 64(1):e15178. PubMed ID: 35510521
[No Abstract] [Full Text] [Related]
39. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.
Nachtigall I; Bonsignore M; Hohenstein S; Bollmann A; Günther R; Kodde C; Englisch M; Ahmad-Nejad P; Schröder A; Glenz C; Kuhlen R; Thürmann P; Meier-Hellmann A
BMC Infect Dis; 2022 Mar; 22(1):291. PubMed ID: 35346089
[TBL] [Abstract][Full Text] [Related]
40. More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Taytard J; Prevost B; Corvol H
N Engl J Med; 2022 Mar; 386(12):1191-1192. PubMed ID: 35235722
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
